Novartis CEO Daniel Vasella says it is unlikely that his companys Prexige (lumiracoxib) painkiller will gain FDA approval after being pulled from the market in Australia earlier this year due to safety concerns.
Sepracor enters Lunesta marketing pact with GSK for Europe, Japan
In hopes to boost its profits amid cheaper competition, Sepracor has entered into a marketing deal with GlaxoSmithKline to market its sleep drug Lunesta outside North America.
Two new studies have once again called into question the safety of GlaxoSmithKlines type 2 diabetes drug Avandia.
Company news
September 11, 2007
4:00 am
Validus Pharmaceuticals announced that it has acquired bipolar disorder treatment Equetro (carbamazepine) extended release capsules from Shire.
Product news
September 11, 2007
4:00 am
Quinnova Pharmaceuticals announced the commercial launch of Tersi Foam, (2.25% selenium sulfide) for the treatment of seborrheic dermatitis and tinea versicolor of the skin.
Sanofi-Aventis settles federal lawsuit for $182.8 million
Sanofi-Aventis agreed to pay $182.8 million plus interest to resolve lawsuits under the federal Claims Act relating to Anzemet and involving predecessor company Aventis Pharmaceuticals.
Pfizer has issued a Dear doctor letter warning healthcare professionals of the presence of a potential carcinogen in Viracept and cautioning against its use in pregnant women and pediatric patients, FDA said.
Bayer’s Trasylol raises kidney risk: FDA regulators
FDA regulators said that Bayers injectable Trasylol, used to control bleeding in bypass surgery, raised the risk of kidney damage in clinical studies and may also increase the chance of death in patients.